| Field | Specification |
|---|---|
| Target | |
| Alternative names | Nucleus accumbens-associated protein 1; NAC-1; BTB/POZ domain-containing protein 14B; NACC1; BTBD14B; NAC1 |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human Nac1/NACC1 recombinant protein (Position: E114-E317). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets nucleus accumbens-associated protein 1 (gene NACC1) in human samples and is validated for Western blot, IHC, ICC/IF, flow cytometry and ELISA. The predicted molecular weight is 57.3 kDa, and the supplier reports an observed band at about 68 kDa.
NACC1, also called NAC1, is a BTB/POZ domain transcriptional repressor that recruits histone deacetylases such as HDAC3 and HDAC4. It is expressed in the nucleus accumbens and other tissues, and it is often overexpressed in ovarian and other carcinomas, where it is studied for roles in tumor cell proliferation and survival.
| Target | Nucleus accumbens-associated protein 1 (gene NACC1; UniProt Q96RE7, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 57.3 kDa |
| Observed MW | 68 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human HeLa cells, human MCF-7 cells, human Caco-2 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human bladder epithelial carcinoma tissue, human papillary carcinoma of the left breast tissue, human the renal pelvis is squamous metaplasia tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): MCF-7 cells.
Samples with a confirmed signal (flow cytometry): K562 cells.
Immunogen
Recombinant human Nac1/NACC1 fragment (Glu114–Glu317), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human. UniProt places nucleus accumbens-associated protein 1 in the nucleus and cytoplasm. Tissue expression noted by UniProt (human): Overexpressed in several types of carcinomas including ovarian serous carcinomas. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
